Novltreat 1.7

Noveltreat 1.7mg Injection contains Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is supplied as a single-dose pre-filled pen containing Semaglutide 1.7 mg/0.75 mL and is intended for subcutaneous use once weekly. It is manufactured by Sun Pharmaceutical Industries Ltd. Noveltreat 1.7mg Injection is used for long-term weight management in adults with obesity or overweight with certain weight-related health conditions. It is used along with a reduced-calorie diet and increased physical activity.

Noveltreat 1.7mg Injection may be prescribed for: Long-term weight management: It is used along with a reduced-calorie diet and increased physical activity to help adults with obesity or overweight achieve and maintain weight loss. Weight-related health conditions: It may be used in adults who are overweight or obese and have one or more weight-related health conditions, such as high blood pressure, type 2 diabetes, or abnormal cholesterol levels. The dose is increased gradually according to the treatment schedule prescribed by the doctor. Do not change the dose without medical advice.

Noveltreat 1.7mg Injection is administered as a subcutaneous injection once a week. It can be injected into the abdomen, thigh, or upper arm and can be used at any time of the day, with or without food. Use it on the same day each week as advised by your doctor. Your doctor or healthcare professional should show you how to use the pre-filled pen before you administer it yourself. Do not inject Noveltreat into a vein or muscle

Common side effects of Noveltreat 1.7mg Injection may include: Nausea Vomiting Diarrhoea Constipation Stomach or abdominal pain Reduced appetite Headache Tiredness These effects are generally more common during dose escalation and may improve as the body adjusts to treatment. Seek medical attention if you develop severe or persistent abdominal pain, especially if the pain spreads to the back, as this may indicate pancreatitis. Gallbladder-related problems and serious allergic reactions also require prompt medical attention

Pregnancy Unsafe Noveltreat 1.7mg Injection is not recommended during pregnancy. If you are planning to become pregnant, discuss Semaglutide treatment with your doctor. Semaglutide should be discontinued at least 2 months before a planned pregnancy. Breast Feeding Consult Your Doctor Tell your doctor if you are breastfeeding before using Noveltreat 1.7mg Injection. Your doctor will decide whether treatment should be continued or avoided based on your individual circumstances. Lungs Consult Your Doctor Noveltreat does not have a specific routine lung-related restriction. However, tell your doctor about any significant respiratory condition. Also inform your healthcare team that you are using Semaglutide before surgery or a procedure requiring anaesthesia or deep sedation because it can delay stomach emptying. Liver Consult Your Doctor Tell your doctor if you have liver disease before using Noveltreat 1.7mg Injection. Your doctor will assess whether any additional monitoring is needed. Alcohol Consult Your Doctor Discuss alcohol consumption with your doctor while using Noveltreat. Alcohol may worsen nausea and other gastrointestinal symptoms and may affect appetite and blood sugar le

2 - 8°C